Jefferies Positive on Amarin's (AMRN) AMR101 New Chemical Entity Prospects
Tweet Send to a FriendGet Alerts AMRN Hot Sheet
Price: $6.78 -2.02%
Rating Summary:
9 Buy, 3 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Rating Summary:
9 Buy, 3 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Trade AMRN Now!
Earlier, analysts at Jefferies commented on Amarin Corporation (NASDAQ: AMRN) after reviewing Lovaza FDA approval documents.
The firm comments, "In our review of Lovaza FDA approval documents, we learned that the FDA originally denied the Lovaza sponsors their request to use EPA-DHA as the generic name for Lovaza, and instead decided that Lovaza was best described as “3-omega acid ethyl esters.” This gives us incrementally higher confidence in AMRN’s ability to carve out EPA as a distinct active moiety and argue for 5 years of new chemical entity exclusivity for AMR101."
Shares of Amarin have been on a wild ride today related to an inadvertent post about FDA approval for AMR101.
The firm maintained their Buy rating price target of $26.00
For an analyst ratings summary and ratings history on Amarin Corporation click here. For more ratings news on Amarin Corporation click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The firm comments, "In our review of Lovaza FDA approval documents, we learned that the FDA originally denied the Lovaza sponsors their request to use EPA-DHA as the generic name for Lovaza, and instead decided that Lovaza was best described as “3-omega acid ethyl esters.” This gives us incrementally higher confidence in AMRN’s ability to carve out EPA as a distinct active moiety and argue for 5 years of new chemical entity exclusivity for AMR101."
Shares of Amarin have been on a wild ride today related to an inadvertent post about FDA approval for AMR101.
The firm maintained their Buy rating price target of $26.00
For an analyst ratings summary and ratings history on Amarin Corporation click here. For more ratings news on Amarin Corporation click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Janney Capital Boosts PT on Gap (GPS) Post Q1
- Needham & Company Boosts Numbers on Infoblox (BLOX) on Strong Q3
- Dollar Tree (DLTR) Beats But Looks Stretched - Jefferies
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Jefferies & Co
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
